Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Naval Daver, Abhishek Maiti, Tapan M. Kadia, et al.
Cancer Discovery (2022) Vol. 12, Iss. 11, pp. 2516-2529
Open Access | Times Cited: 92

Showing 26-50 of 92 citing articles:

Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy
Yangyang Jia, Yanru Wang, Louisa S. Chard, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML
Cheuk Him Man, Wing Lam, Chee-Chean Dang, et al.
Blood (2023) Vol. 142, Iss. 23, pp. 2002-2015
Open Access | Times Cited: 11
Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
Phaedon D. Zavras, Ilias Sinanidis, Panagiotis Tsakiroglou, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 5018-5018
Open Access | Times Cited: 10
Novel immunotherapies in the treatment of AML: is there hope?
Marion Subklewe, Veit Bücklein, David A. Sallman, et al.
Hematology (2023) Vol. 2023, Iss. 1, pp. 691-701
Closed Access | Times Cited: 10
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Jayastu Senapati, Warren Fiskus, Naval Daver, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 21, pp. 4352-4360
Closed Access | Times Cited: 9
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel
Farhad Ravandi, Jacqueline Cloos, Francesco Buccisano, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 12, pp. 1847-1855
Closed Access | Times Cited: 9
Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression
Ashwini Jambhekar, Emily E. Ackerman, Berk A. Alpay, et al.
Deleted Journal (2024) Vol. 1, Iss. 1, pp. 100004-100004
Open Access | Times Cited: 3
Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia
Yi Chen, Jing Zheng, Yimei Weng, et al.
Annals of Hematology (2024) Vol. 103, Iss. 4, pp. 1211-1220
Closed Access | Times Cited: 3
TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment
Linsheng Zhang, Brooj Abro, Andrew T. Campbell, et al.
Laboratory Medicine (2024) Vol. 55, Iss. 6, pp. 686-699
Open Access | Times Cited: 3
Acute myeloid leukemia management and research in 2025
Hagop M. Kantarjian, Courtney D. DiNardo, Tapan M. Kadia, et al.
CA A Cancer Journal for Clinicians (2024)
Open Access | Times Cited: 3
The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
Matteo Piccini, Francesco Mannelli, Giacomo Coltro
Bioengineering (2023) Vol. 10, Iss. 5, pp. 591-591
Open Access | Times Cited: 8
Venetoclax in adult acute myeloid leukemia
Mengci Hu, Wenzhe Li, Youshan Zhang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115820-115820
Open Access | Times Cited: 7
Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression
Scott S. Auerbach, Beana Puka, Upendarrao Golla, et al.
Life (2024) Vol. 14, Iss. 3, pp. 309-309
Open Access | Times Cited: 2
Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia
Kai Wang, Meixu Jiang, Huimin Liu, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107319-107319
Closed Access | Times Cited: 2
Venetoclax-Related Neutropenia in Leukemic Patients: A Comprehensive Review of the Underlying Causes, Risk Factors, and Management
Laura Giuseppina Di Pasqua, Murwan Mahmoud Abdallah, Fausto Feletti, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 484-484
Open Access | Times Cited: 2
Therapy-Related Myeloid Neoplasm: Biology and Mechanistic Aspects of Malignant Progression
Serena Travaglini, Massimiliano Marinoni, Valeria Visconte, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1054-1054
Open Access | Times Cited: 2
Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice
Rasoul Pourebrahim, Rafael Heinz Montoya, Hiroki Akiyama, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 5, pp. 101558-101558
Open Access | Times Cited: 2
Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia
Mihir Shukla, Maher Abdul‐Hay, Jun‐Hui Choi
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1768-1768
Open Access | Times Cited: 2
Evolving Risk Classifications in AML in a Real-Life Scenario: After Changes upon Changes, Is It More and More Adverse?
Clara Aparicio-Pérez, Esther Prados de la Torre, Joaquín Sánchez‐García, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1425-1425
Open Access | Times Cited: 5
Basic mechanisms and novel potential therapeutic targets for ferroptosis in acute myeloid leukemia
Xiao Tang, Yin Wang, Yu Zhu, et al.
Annals of Hematology (2023) Vol. 102, Iss. 8, pp. 1985-1999
Closed Access | Times Cited: 5
Insights into the New Molecular Updates in Acute Myeloid Leukemia Pathogenesis
Derya Demir
Genes (2023) Vol. 14, Iss. 7, pp. 1424-1424
Open Access | Times Cited: 5
Azacitidine combined with venetoclax alleviates AML-MR with TP53 mutation in SDS: a case report and literature review
MA Cui-ping, Haiyan Lang, Yuhan Chen, et al.
Anti-Cancer Drugs (2024)
Closed Access | Times Cited: 1
Evaluating targeted therapies in older patients with TP53 -mutated AML
Jean Sabile, Ronan T. Swords, Jeffrey W. Tyner
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 9, pp. 1201-1218
Closed Access | Times Cited: 1
The role of clonal progression leading to the development of therapy-related myeloid neoplasms
Luca Guarnera, Maria Rosaria Pascale, Hajro Hajrullaj, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3507-3517
Open Access | Times Cited: 1
Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment
Monika Chomczyk, Luca Gazzola, Shubhankar Dash, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1

Scroll to top